Hydralazine + Magnesium Valproate as Epigenetic Treatment for Myelodysplastic Syndrome (MDS). Preliminary Results of a Phase II Trial.

MLA

Candelaria, Myrna, et al. “Hydralazine + Magnesium Valproate as Epigenetic Treatment for Myelodysplastic Syndrome (MDS). Preliminary Results of a Phase II Trial.” Blood, vol. 114, no. 22, Nov. 2009, p. 1767. EBSCOhost, https://doi.org/10.1182/blood.V114.22.1767.1767.

APA

Candelaria, M., Herrera, A., Labardini, J., Gonzalez-Fierro, A., Trejo-Becerril, C., de la Cruz-Hernandez, E., la Torre-Talavera, B. A., & Duenas-Gonzalez, A. (2009). Hydralazine + Magnesium Valproate as Epigenetic Treatment for Myelodysplastic Syndrome (MDS). Preliminary Results of a Phase II Trial. Blood, 114(22), 1767. https://doi.org/10.1182/blood.V114.22.1767.1767

Chicago

Candelaria, Myrna, Aquileo Herrera, Juan Labardini, Aurora Gonzalez-Fierro, Catalina Trejo-Becerril, Erick de la Cruz-Hernandez, Brenda A la Torre-Talavera, and Alfonso Duenas-Gonzalez. 2009. “Hydralazine + Magnesium Valproate as Epigenetic Treatment for Myelodysplastic Syndrome (MDS). Preliminary Results of a Phase II Trial.” Blood 114 (22): 1767. doi:10.1182/blood.V114.22.1767.1767.